Search hospitals
>
New York
>
New York
Icahn School of Medicine at Mount Sinai
Claim this profile
New York, New York 10029
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Solid Tumors
Conducts research for Multiple Myeloma
1544 reported clinical trials
158 medical researchers
Summary
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Solid Tumors, Multiple Myeloma and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,438 conditions. There are 158 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Deborah Doroshow, MD, PhD, and Thomas Marron, MD PhD.
Area of expertise
Cancer
Icahn School of Medicine at Mount Sinai has run 85 trials for Cancer. Some of their research focus areas include:
Lung Cancer
Icahn School of Medicine at Mount Sinai has run 57 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Edward J. Kim
University of California Davis Comprehensive Cancer Center
2 years of reported clinical research
Matthew Galsky, M.D.
Icahn School of Medicine at Mount Sinai
6 years of reported clinical research
Deborah Doroshow, MD, PhD
Mount Sinai Hospital
5 years of reported clinical research
Thomas Marron, MD PhD
Icahn School of Medicine at Mount Sinai
3 years of reported clinical research
Clinical Trials running at Icahn School of Medicine at Mount Sinai
Breast Cancer
Crohn's Disease
Ovarian Cancer
Pompe Disease
Inflammatory Bowel Disease
Cancer
Prostate Cancer
Asthma
Ulcerative Colitis
Fallopian Tube Cancer
Ribociclib + Hormone Therapy
for Breast Cancer
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
Recruiting
2 awards
Phase 3
4 criteria
Elacestrant
for Breast Cancer
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting
2 awards
Phase 3
3 criteria
Combination Immunotherapy + Radiation
for Cancer
This is a combination of 4 therapies, three of which are used to treat a single "target site" of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into the blood stream (intravenous or "IV"). 1. Radiation: The target site --lymph node or tumor (the one what will be injected) --will get two small treatments of radiation. Radiation is often times used to shrink and kill tumors in patients with certain types of lymphoma, breast cancer and head and neck cancer, however, the dose of radiation that you will receive --one dose on day one of the clinical trial and one dose on day two --is 10 to 20 time less radiation that you would receive for treatment of these cancers. 2. Flt3L/CDX-301 is an immune cell growth factor, similar to white blood cell growth factors (Neupogen or Neulasta) or red blood cell growth factors (EPO or Epogen) that you may have received to help protect your blood cells previously. Flt3L causes your body to make more immune cells, specifically a type of immune cell called "dendritic cells". 3. Poly-ICLC is an immune cell activating factor. Its function is to turn on the immune cells that have been brought to the tumor by Flt3L. 4. Pembrolizumab is an antibody (a type of human protein) that is being tested to see if it will allow the body's immune system to kill your tumor cells. Pembrolizumab is approved for use by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with many different types of cancer including head and neck cancer. Pembrolizumab is not FDA approved to treat patients with non-Hodgkin's lymphoma or metastatic breast cancer, as it has not been effective at treating these cancers when used alone. While most people do not have immediate side effects when this medication is given, it has the ability to cause side effects for.
Recruiting
2 awards
Phase 1 & 2
2 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Icahn School of Medicine at Mount Sinai?
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Solid Tumors, Multiple Myeloma and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,438 conditions. There are 158 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Deborah Doroshow, MD, PhD, and Thomas Marron, MD PhD.
Where is Icahn School of Medicine at Mount Sinai located?
The Icahn School of Medicine at Mount Sinai is situated in Manhattan, New York, nestled on the Upper East Side between Fifth and Madison Avenues, covering East 98th to 102nd Streets. Accessible by subway line number 6 and bus lines M1, M2, M3, M4, M96, M98, M101, M102, M103, M106. For comprehensive public transit details, visit the Metropolitan Transportation Authority (MTA) website.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Icahn School of Medicine at Mount Sinai:** - **Department of Patient Financial Services:** For financial assistance applications and eligibility inquiries, contact (212) 731-3100 or visit One Gustave L. Levy Place, Box 6000, New York, New York 10029. **Insurance Inquiries:** - **Customer Service Billing Office:** For insurance and billing questions, call (212) 987-3100, Monday-Friday, 8 am – 6 pm. - **Mount Sinai Doctors Faculty Practice:** Participates in most insurance plans, including Medicare. Verify acceptance and discuss requirements by contacting the physician's office or your insurance company directly.
What insurance does Icahn School of Medicine at Mount Sinai accept?
The Icahn School of Medicine at Mount Sinai, part of the Mount Sinai Health System, participates in numerous health plan networks. It's important to verify that both the hospital and the physicians involved in your care accept your insurance plan. For detailed information on physician insurance participation, use the "Find a Doctor" feature at www.mountsinai.org, and for hospital-specific insurance information, direct inquiries to the respective departments or visit the hospital's website.
What awards or recognition has Icahn School of Medicine at Mount Sinai received?
The Icahn School of Medicine at Mount Sinai has been awarded a five-year, $55.5 million Clinical and Translational Science Award by the National Center for Advancing Translational Sciences, part of the NIH. This funding supports ConduITS, the Institute for Translational Sciences at Mount Sinai, enhancing its role in the CTSA Program, which includes 63 nationwide sites. It will boost Mount Sinai's capabilities in translational research informatics, digital health, and data science, accelerating research translation into discoveries for improved health outcomes across diverse populations.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.